Premium
ZANUBRUTINIB FOR PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Author(s) -
Xu W.,
Yang S.,
Zhou K.,
Pan L.,
Li Z.,
Zhou J.,
Gao S.,
Zhou D.,
Hu J.,
Feng R.,
Huang H.,
Ji M.,
Guo H.,
Huang J.,
Novotny W.,
Feng S.,
Li J.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.55_2629
Subject(s) - medicine , ibrutinib , neutropenia , refractory (planetary science) , gastroenterology , discontinuation , chronic lymphocytic leukemia , phases of clinical research , progressive disease , clinical trial , toxicity , leukemia , chemotherapy , physics , astrobiology